Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...
A law that coaxed companies to lower the price of drugs came with a little-known consequence: smaller discounts for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback